Tradestie Institutional Equity Comparison Engine · Market Close Mar 03, 2026

MNMD vs VTYX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTYX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 2–3 Matrix Metrics)

VTYX Overall Winner 6-Pillar Tally: MNMD 1 – 3 VTYX (2 Tie) Matrix Metrics: MNMD 3 – 2 VTYX

As of Mar 03, 2026, Ventyx Biosciences, Inc. (VTYX) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MNMD carries a Unified Composite Score of 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin), whereas VTYX carries 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNMD vs VTYX
MNMD NASDAQ
Mind Medicine (MindMed) Inc. Common Shares
Medicinal Chemicals & Botanical Products
$15.02
+1.01% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.79β · 55% Vol
Unified Composite Score
63.1 / 100 BUY
Tech 75.0 Fund 62.0 Flow 60.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $13.52 · SMA50: $12.57
VTYX NASDAQ Head-to-Head Winner
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.07β · 2% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.0% over 20 days), RSI 71
RSI-14: 70.7 · SMA20: $13.96 · SMA50: $12.72

6-Pillar Scorecard Institutional Category Breakdown (MNMD 1 – 3 VTYX)

Columns: Metric · MNMD · VTYX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale MNMD
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $1.4B $1.0B
3. Profitability & Quality VTYX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -85.6% -45.4%
4. Balance Sheet & Cash Flow VTYX
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.70 Book/Sh · -85.6% ROE $2.68 Book/Sh · -45.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTYX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 70.7% (6th %ile) 0.5% (<1st %ile)
Put/Call OI Skew 0.18x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNMD (3) vs VTYX (2)
Institutional Metric MNMD VTYX Criterion Row Edge
Market Capitalization
Scale
$1.4B $1.0B Larger Scale MNMD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-85.6% -45.4% Higher ROE VTYX
52-Week Range Position
Momentum
98% ($5–$15) 55% ($1–$25) Stronger Trend MNMD
Beta / 30D Volatility
Risk Regime
1.79β · 55% Vol 2.07β · 2% Vol Lower Realized Risk VTYX
Unified Institutional Score
Composite Signal
63.1 / 100 (BUY) 50.4 / 100 (HOLD) Higher Composite MNMD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.70 Book/Sh · -85.6% ROE) N/A ($2.68 Book/Sh · -45.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTYX +48.66 pp
MNMD: +19.54% · VTYX: +68.2%
3M Horizon VTYX +260.71 pp
MNMD: +19.02% · VTYX: +279.73%
6M Horizon VTYX +267.75 pp
MNMD: +75.06% · VTYX: +342.81%
1Y Horizon VTYX +653.71 pp
MNMD: +123.51% · VTYX: +777.22%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNMD vs VTYX. Trailing 12-month operating profitability (MNMD 0.0% vs VTYX 0.0%) and valuation multiples (MNMD N/M vs VTYX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MNMD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.6% · N/M
VTYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNMD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 70.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MNMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VTYX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MNMD vs VTYX Key Questions & Quantitative Answers

As of Mar 03, 2026, Ventyx Biosciences, Inc. (VTYX) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MNMD carries a Unified Composite Score of 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin), whereas VTYX carries 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).

MNMD leads the Growth & Scale pillar: MNMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VTYX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MNMD generates N/A in USD-normalized revenue versus N/A for VTYX. In operating R&D and SG&A reinvestment, MNMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTYX.

MNMD and VTYX trade at balanced relative valuation multiples. MNMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNMD (-85.6% ROE) versus VTYX (-45.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MNMD carries 70.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 55% Vol realized risk). By comparison, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Mar 03, 2026. For educational research only; not investment advice.